Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GNTA with free AI briefings, catalyst countdowns, and dilution alerts.

GNTA · Genenta Science S.p.A.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$28.1M Cash on Hand
49.2mo Cash Runway
Follow GNTA by email Get an email when GNTA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GNTA, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Autologous CD34+-enriched HSPCs Transduced with… Glioblastoma Multiforme Phase 1/2 · NCT03866109 Terminated

Also used in these trials (approved or third-party drugs, not GNTA's own candidates): Cabozantinib, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GNTA holds $28.1M in cash and short-term investments and burns about $1.7M/quarter from operations, an estimated runway of 49.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 29 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GNTA files for a raise →

👥 Who Owns GNTA

Insiders 0.3% Other 5%+ holders 23.7% Institutions (14 holders) 4.7% Public and other holders 71.3%
HolderTypeShares% of sharesAs of
Marco Nuzzo 5%+ holder (13D) 5,543,910 23.66% 2026-05-29
Miguel Maria Mutti
Director · +20,000 options
Insider 33,333 0.14% 2026-03-18
Pierluigi Paracchi
Chief Executive Officer, Director, 10% o · +100,000 options
Insider 27,000 0.12% 2026-03-18
Richard B Slansky
Chief Financial Officer · +80,000 options
Insider 2,200 0.01% 2026-03-18

Share count 23,432,183 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GNTA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GNTA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.